| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial.
|
Cancer
|
2008
|
3.68
|
|
2
|
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
|
J Clin Oncol
|
2011
|
2.87
|
|
3
|
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial.
|
J Clin Oncol
|
2004
|
2.55
|
|
4
|
Defining the critical hurdles in cancer immunotherapy.
|
J Transl Med
|
2011
|
2.32
|
|
5
|
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
|
Blood
|
2008
|
1.86
|
|
6
|
Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants.
|
Clin Cancer Res
|
2010
|
1.76
|
|
7
|
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
|
J Clin Invest
|
2002
|
1.74
|
|
8
|
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation.
|
Blood
|
2004
|
1.73
|
|
9
|
Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature.
|
World J Surg Oncol
|
2008
|
1.73
|
|
10
|
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
|
Clin Cancer Res
|
2007
|
1.66
|
|
11
|
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
|
Cancer Res
|
2011
|
1.61
|
|
12
|
Distress reduction from a psychological intervention contributes to improved health for cancer patients.
|
Brain Behav Immun
|
2007
|
1.59
|
|
13
|
Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
|
J Immunol
|
2006
|
1.58
|
|
14
|
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
|
Clin Cancer Res
|
2004
|
1.55
|
|
15
|
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
|
Mol Cancer Ther
|
2009
|
1.54
|
|
16
|
β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption.
|
Brain Behav Immun
|
2012
|
1.50
|
|
17
|
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
|
Ann Surg Oncol
|
2007
|
1.49
|
|
18
|
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.
|
Cancer Immunol Immunother
|
2011
|
1.47
|
|
19
|
Melanoma, version 2.2013: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.44
|
|
20
|
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
|
J Natl Cancer Inst
|
2004
|
1.42
|
|
21
|
Precancerous stem cells have the potential for both benign and malignant differentiation.
|
PLoS One
|
2007
|
1.36
|
|
22
|
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
|
Cancer Res
|
2006
|
1.32
|
|
23
|
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
|
Mol Cancer
|
2010
|
1.27
|
|
24
|
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
|
Blood
|
2008
|
1.26
|
|
25
|
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
|
J Immunol
|
2011
|
1.25
|
|
26
|
IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
|
J Immunol
|
2007
|
1.23
|
|
27
|
A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial.
|
Psychosom Med
|
2009
|
1.22
|
|
28
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
Breast Cancer Res Treat
|
2008
|
1.21
|
|
29
|
Review of S100A9 biology and its role in cancer.
|
Biochim Biophys Acta
|
2012
|
1.19
|
|
30
|
Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments.
|
Brain Behav Immun
|
2006
|
1.18
|
|
31
|
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
|
J Clin Invest
|
2003
|
1.17
|
|
32
|
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
|
Clin Cancer Res
|
2007
|
1.16
|
|
33
|
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
|
J Immunol
|
2005
|
1.15
|
|
34
|
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
|
Cancer Res
|
2008
|
1.11
|
|
35
|
Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis.
|
Cancer Immunol Immunother
|
2008
|
1.08
|
|
36
|
Melanoma, version 4.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.07
|
|
37
|
Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients.
|
Psychooncology
|
2012
|
1.05
|
|
38
|
Myeloid-derived suppressor cells in breast cancer.
|
Breast Cancer Res Treat
|
2013
|
1.04
|
|
39
|
Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients.
|
Cell Immunol
|
2011
|
1.03
|
|
40
|
STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha.
|
Cancer Immunol Immunother
|
2007
|
1.03
|
|
41
|
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
1.02
|
|
42
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
Clin Cancer Res
|
2002
|
1.02
|
|
43
|
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
|
J Clin Oncol
|
2009
|
1.02
|
|
44
|
Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
|
Clin Cancer Res
|
2008
|
1.02
|
|
45
|
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.
|
J Clin Oncol
|
2012
|
1.01
|
|
46
|
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
|
Clin Cancer Res
|
2006
|
1.00
|
|
47
|
Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer.
|
Ann Surg Oncol
|
2006
|
0.99
|
|
48
|
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.
|
Cancer Immunol Immunother
|
2014
|
0.97
|
|
49
|
IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
|
J Immunol
|
2004
|
0.97
|
|
50
|
Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
|
Cancer Immunol Immunother
|
2005
|
0.96
|
|
51
|
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
|
Clin Cancer Res
|
2010
|
0.96
|
|
52
|
Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
|
Surgery
|
2012
|
0.95
|
|
53
|
Delayed emotional recovery after taxane-based chemotherapy.
|
Cancer
|
2008
|
0.93
|
|
54
|
Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors.
|
J Surg Res
|
2007
|
0.93
|
|
55
|
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
|
J Immunother
|
2011
|
0.93
|
|
56
|
Fatigue and herpesvirus latency in women newly diagnosed with breast cancer.
|
Brain Behav Immun
|
2011
|
0.93
|
|
57
|
Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
|
Cancer Res
|
2005
|
0.93
|
|
58
|
Re-emphasizing the concept of adequacy of intraoperative assessment of the axillary sentinel lymph nodes for identifying nodal positivity during breast cancer surgery.
|
World J Surg Oncol
|
2007
|
0.92
|
|
59
|
Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer.
|
Health Psychol
|
2011
|
0.92
|
|
60
|
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
61
|
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
|
J Clin Oncol
|
2005
|
0.90
|
|
62
|
Melanoma.
|
J Natl Compr Canc Netw
|
2012
|
0.90
|
|
63
|
Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
|
J Immunother
|
2012
|
0.90
|
|
64
|
Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival.
|
Exp Eye Res
|
2012
|
0.89
|
|
65
|
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways.
|
Blood
|
2006
|
0.89
|
|
66
|
Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.
|
BMC Cancer
|
2010
|
0.88
|
|
67
|
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
|
Mol Cancer Ther
|
2010
|
0.88
|
|
68
|
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
|
J Immunol
|
2003
|
0.87
|
|
69
|
NK cell-based immunotherapy for treating cancer: will it be promising?
|
Korean J Hematol
|
2011
|
0.87
|
|
70
|
VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.
|
J Interferon Cytokine Res
|
2008
|
0.87
|
|
71
|
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
|
Cancer Immunol Immunother
|
2008
|
0.85
|
|
72
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
J Immunother
|
2005
|
0.84
|
|
73
|
Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.
|
Cancer Immunol Immunother
|
2011
|
0.84
|
|
74
|
IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
|
Clin Cancer Res
|
2008
|
0.84
|
|
75
|
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
|
J Immunother
|
2014
|
0.84
|
|
76
|
Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment.
|
J Control Release
|
2011
|
0.83
|
|
77
|
Patterns of recurrence after sentinel lymph node biopsy for breast cancer.
|
Ann Surg Oncol
|
2003
|
0.82
|
|
78
|
Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
|
Surgery
|
2006
|
0.82
|
|
79
|
Immune modulation with interleukin-21.
|
Ann N Y Acad Sci
|
2009
|
0.82
|
|
80
|
Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta.
|
Arthritis Res Ther
|
2013
|
0.82
|
|
81
|
Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function.
|
Brain Behav Immun
|
2011
|
0.81
|
|
82
|
Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy.
|
World J Surg Oncol
|
2008
|
0.81
|
|
83
|
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response.
|
Am J Transl Res
|
2013
|
0.80
|
|
84
|
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
|
J Immunother
|
2014
|
0.80
|
|
85
|
Heparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury.
|
J Pediatr Surg
|
2013
|
0.80
|
|
86
|
Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
|
Radiology
|
2013
|
0.79
|
|
87
|
A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
|
Am J Clin Oncol
|
2011
|
0.79
|
|
88
|
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
|
Cancer Immunol Immunother
|
2009
|
0.79
|
|
89
|
Folate-immunoglobulin G as an anticancer therapeutic antibody.
|
Bioconjug Chem
|
2010
|
0.78
|
|
90
|
Release of biologically functional interferon-alpha from a nanochannel delivery system.
|
Biomed Microdevices
|
2005
|
0.78
|
|
91
|
Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer.
|
Altern Ther Health Med
|
2012
|
0.78
|
|
92
|
Cognitive problems among breast cancer survivors: loneliness enhances risk.
|
Psychooncology
|
2014
|
0.77
|
|
93
|
Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells.
|
Vet Immunol Immunopathol
|
2013
|
0.77
|
|
94
|
Novel cytokines in the treatment of malignancies.
|
Cancer Treat Res
|
2005
|
0.76
|
|
95
|
Correction to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048-1060.
|
Oncoimmunology
|
2013
|
0.76
|
|
96
|
Individualized local treatment strategies for in-transit melanoma.
|
Oncology (Williston Park)
|
2011
|
0.75
|
|
97
|
Getting melanoma cells to stimulate with frequency.
|
J Clin Oncol
|
2005
|
0.75
|
|
98
|
Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
|
Melanoma Res
|
2016
|
0.75
|
|
99
|
Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010.
|
J Immunother
|
2010
|
0.75
|
|
100
|
A naonoporous cell-therapy device with controllable biodegradation for long-term drug release.
|
J Control Release
|
2012
|
0.75
|
|
101
|
Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma.
|
Cancer Immunol Immunother
|
2002
|
0.75
|
|
102
|
Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.
|
Pac Symp Biocomput
|
2018
|
0.75
|